“…Individual patient quality assurance (QA) is required for MLC‐involved intensity‐modulated plans (i.e., intensity‐modulated radiation therapy (IMRT) and volumetric‐modulated arc therapy (VMAT)) to verify agreement between the planned and delivered doses, which is critical for patient care
(1)
. Over two decades, MLC properties, their uncertainties, and their potential clinical effects have been extensively investigated
2
,
3
,
4
,
5
,
6
,
7
,
8
,
9
,
10
,
11
,
12
. With recently developed narrow leaf MLC systems and their applications in hypofractionated treatment, it is necessary to more accurately determine the properties and associated uncertainties.…”